Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal ...
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) ...
BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast ...
Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer Immune stimulating components of ...
Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University ...
Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC ...
PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical ...
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker ...
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro ...
Accessibility Tools
